RELMADA THERAPEUTICS, INC. (OTCMKTS:RLMD) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.
Item 1.02 Termination of a Material Definitive Agreement
Effective January 1, 2019, Relmada Therapeutics, Inc. (the “Company”) changed its corporate headquarters to 880 3rd Ave, 12thfloor, New York, NY 10022 (the “Premises”). to a Lease Agreement, effective January 1, 2019 (the “Lease Agreement”), between the Company and 880 Third Avenue Tenant LLC, the Company now occupies a portion of the 12thFloor at 880 3rd Ave, New York, NY 10022. The monthly rental fee for the Premises is $7,513 per month. The Lease Agreement expires on December 31, 2019. Effective January 1, 2019, the Company terminated its current lease agreement, dated May 2, 2017, with Regus Management Group, LLC for space at 750 Third Avenue, 9th Floor, New York, NY 10017. A copy of the Lease Agreement will be included as an exhibit to the Company’s Form 10-Q for the quarter ended December 31, 2018.
About RELMADA THERAPEUTICS, INC. (OTCMKTS:RLMD)
Relmada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to treat chronic pain. Its product candidates include d-Methadone (dextromethadone, REL-1017), LevoCap ER (REL-1015), BuTab (REL-1028) and MepiGel (REL-1021). Its d-Methadone is an N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of neuropathic pain. Its REL-1015 is an extended release, abuse deterrent formulation of the opioid analgesic levorphanol, which is pharmacologically differentiated from morphine, oxycodone and other opioids for the management of pain severe enough to require daily, around-the-clock and long-term opioid treatment. REL-1028 represents formulations of oral, modified release buprenorphine being developed for both chronic pain and opioid dependence indications. REL-1021 is a topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies.